newsfilter
← Latest News
GlobeNewswire·

Oculis Reports Q2 2025 Financial Results and Provides Company Update

Focused execution in Q2 2025 to advance Oculis' pipeline in ophthalmology and neuro-ophthalmologyOCS-01: Both pivotal Ph3 DIAMOND trials are fully enrolled, with topline results expected in Q2 2026 for the first